Correction: Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM)

Affiliations

• ¹ Department of Breast and Endocrine Surgery, Osaka International Cancer Institute, Osaka, Japan.
• ² Department of Breast Oncology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan. nniikura@tokai.ac.jp.
• ³ Department of Breast Surgery and Oncology, Kanagawa Cancer Center, Kanagawa, Japan.
• ⁴ Department of Breast Oncology, Hokkaido Cancer Center, Hokkaido, Japan.
• ⁵ Department of Breast Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
• ⁶ Division of Breast Oncology, Saitama Cancer Center, Saitama, Japan.
• ⁷ Department of Breast Surgery, Kitano Hospital, Osaka, Japan.
• ⁸ First Department of Surgery, University of the Ryukyus Hospital, Okinawa, Japan.
• ⁹ Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
• ¹⁰ Department of Breast Surgery, JCHO Kurume General Hospital, Fukuoka, Japan.
• ¹¹ Department of Breast Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
• ¹² Cancer Treatment Center, Kansai Medical University Hospital, Osaka, Japan.
• ¹³ Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan.
• ¹⁴ Department of Breast Oncology, Aichi Cancer Center, Aichi, Japan.
• ¹⁵ Department of Diagnostic Imaging and Nuclear Medicine, Tokyo Women's Medical University, Tokyo, Japan.
• ¹⁶ Oncology Medical Science Department I, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
• ¹⁷ Data Intelligence Department, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
• ¹⁸ Advanced Cancer Translational Research Institute, Showa University, Tokyo, Japan.